Given that up to 42% of patients with EIN [48] may ultimately have concurrent cancer at the time of hysterectomy, accurately risk stratifying those who opt to forego hysterectomy may provide valuable prognostic data, particularly due to our findings of TP53 mutations in EIN specimens. This evidence concerns the gene TP53 and cancer.